eligibility_summary
Include: 18–75, histology‑proven R/R DLBCL (NOS incl GCB/ABC, PMBCL, T‑cell–rich, HGBL double/triple hit, EBV+/HHV‑8+), ≥1 lesion ≥1 cm, ECOG 0–2, life ≥3 mo, neg preg test/contraception. Exclude: bleeding risk or surgery <6 wks, stroke/ICH <6 mo, cannot stop strong/mod CYP3A inhibitors, prior transplant, other cancers, active infection/comorbidity or organ/lab dysfunction, high HBV/HCV VL, HIV/syphilis, pregnancy/lactation, CNS disease, severe GI issues, <2 wks antitumor drugs, poor compliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drugs and mechanisms: Zanubrutinib—oral small-molecule, covalent BTK inhibitor that blocks B‑cell receptor (BCR) signaling, Polatuzumab vedotin—CD79b‑directed antibody‑drug conjugate delivering MMAE, a microtubule inhibitor, Bendamustine—alkylating agent causing DNA cross‑linking and apoptosis, Rituximab—anti‑CD20 monoclonal antibody mediating B‑cell depletion via ADCC/CDC/apoptosis. Targets/cells/pathways: malignant B cells in relapsed/refractory DLBCL, BTK/BCR signaling cascade, CD79b on the BCR complex, CD20 on mature B cells, microtubules (via MMAE), DNA integrity/repair pathways (via bendamustine). Study: single‑arm phase II Pola‑ZBR induction (4–6 cycles), optional auto‑HSCT or additional cycles, followed by 1‑year zanubrutinib maintenance.